Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SER
SER logo

SER Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Serina Therapeutics Inc (SER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.490
1 Day change
-8.02%
52 Week Range
7.920
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Serina Therapeutics Inc (SER) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company is experiencing significant financial declines, lacks positive trading trends, has no recent news or catalysts, and technical indicators suggest a bearish trend. Additionally, there are no proprietary trading signals or influential trades to support a buy decision.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.458 and resistance at 1.68. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

  • NULL identified. No recent news, no significant insider or hedge fund activity, and no congressional trading data.

Neutral/Negative Catalysts

  • is down -1.06%, indicating a weak market environment.

Financial Performance

In Q3 2025, Serina Therapeutics reported a complete revenue drop to 0, a net income loss of -$4,585,000 (-425.18% YoY), and an EPS decline to -0.44 (-438.46% YoY). Despite a gross margin of 100%, the financials show no signs of growth or recovery.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast SER stock price to rise
1 Analyst Rating
Wall Street analysts forecast SER stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.620
sliders
Low
11
Averages
11
High
11
Current: 1.620
sliders
Low
11
Averages
11
High
11
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$15
AI Analysis
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$15
AI Analysis
2025-07-14
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.
Jones Trading
Justin Walsh
Strong Buy
Initiates
$11
2025-03-11
Reason
Jones Trading
Justin Walsh
Price Target
$11
2025-03-11
Initiates
Strong Buy
Reason
JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug delivery and soon-to-be clinical stage biotech company that went public via a reverse merger with AgeX Therapeutics in March of last year whose lead asset, SER-252, is being developed for the management of motor fluctuations and dyskinesia in patients with advanced Parkinson's Disease. The firm has "high confidence" that SER-252 will at least match the efficacy observed with other apomorphine delivery approaches, such as Supernus' (SUPN) recently approved Onapgo, while delivering improved tolerability and convenience, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SER
Unlock Now

People Also Watch